Nanologica AB

NICA

SE0005454873

Commodity Chemicals

Delayed Nasdaq Stockholm Other stock markets 16:05:11 11/06/2026 BST			5-day change	1st Jan Change
0.5760 ^SEK	+1.41%		+8.68%	-26.15%

06-01	Nanologica CFO to Step Down	MT
06-01	Nanologica CFO Eva Osterman to step down	FW

Nanologica reshuffles management team following acquisition

Published on 04/23/2026 at 10:38 am BST

Finwire - Translated by Marketscreener - See original

NANOLOGICA AB

+1.41%

Life science company Nanologica is implementing changes to its executive management team following the acquisition of Syntagon. The restructuring will take effect on May 1, according to a press release.

The management team will subsequently consist of CEO Andreas Bhagwani, Annette Roos, CEO of the subsidiary Syntagon, and CFO Eva Osterman.

Latest news about Nanologica AB

06-01	Nanologica CFO to Step Down	MT
06-01	Nanologica CFO Eva Osterman to step down	FW
06-01	Nanologica's CFO leaves	RE
06-01	Nanologica CFO Eva Osterman to step down	FW
06-01	Nanologica AB Announces Resignation of Eva Osterman from Chief Financial Officer, Effective August 31, 2026	CI
05-25	Redeye resumes coverage of Nanologica - sets fair value at SEK 1.7	FW
05-20	Nanologica reports sharp improvement in operating profit following acquisition	FW
05-20	Nanologica AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-27	Nanologica subsidiary appoints Head of Sales	FW
04-23	Nanologica reshuffles management team following acquisition	FW
04-23	Nanologica AB Announces Changes to Management Team, Effect on 1 May 2026	CI
04-21	Nanologica CEO Andreas Bhagwani acquires shares worth approximately SEK 1 million	FW
04-17	Nanologica Secures SEK2 Million Silica-based Purification Media Order	MT
04-17	Nanologica secures SEK 2 million order in India	FW
04-17	Nanologica gets order of about SEK 2 mln from customer in India	RE

Chart Nanologica AB

Duration

Period

NICA: Dynamic Chart

Company Profile

Nanologica AB (publ) is a Sweden-based materials development company. The Company specializes in developing nanoporous materials from nanoporous silica (silicon dioxide) for a variety of applications, ranging from purification to pharmaceutical excipients. The Company's core competency has been developed and expanded in two areas of application, in particular: Drug Delivery and Chromatography, a technology used for the separation and purification of products on the market and in development. The Company's Drug Delivery sector operates within a niche domain of nanocarriers. Nanologica AB (publ)â€™s drug delivery technology is aimed on absorption of the medicine by the body for drugs that are poorly soluble in water.

Employees

Sector

Commodity Chemicals

Calendar

08-27 - Earnings release - Q2 2026

More about the company